Lyra Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2018
Net Income	-28.92	-93.44	-62.68	-55.28	-43.51	Upgrade
Depreciation & Amortization	0.46	0.47	0.28	1.07	1	Upgrade
Other Amortization	-	0.14	-	-	-	Upgrade
Loss (Gain) From Sale of Assets	-0.01	-	-	-	-	Upgrade
Asset Writedown & Restructuring Costs	-	24.72	1.59	1.32	-	Upgrade
Loss (Gain) From Sale of Investments	-	-2.28	-3.5	-0.49	-	Upgrade
Stock-Based Compensation	2.34	6.72	5.89	5.45	2.77	Upgrade
Change in Accounts Payable	-0.52	-1.89	0.45	-2.41	2.35	Upgrade
Change in Unearned Revenue	-0.4	-1.53	-1.56	3.64	11.72	Upgrade
Change in Other Net Operating Assets	-1.81	-2.93	-3.78	3.33	-0.14	Upgrade
Operating Cash Flow	-28.86	-70.01	-63.3	-43.39	-25.82	Upgrade
Capital Expenditures	-0.12	-2.34	-1.05	-0.16	-3.39	Upgrade
Sale of Property, Plant & Equipment	0.02	-	-	-	-	Upgrade
Investment in Securities	-	82.64	-11.54	-64.84	-	Upgrade
Investing Cash Flow	-0.1	80.31	-12.58	-65.01	-3.39	Upgrade
Issuance of Common Stock	5	8.82	69.35	100.5	0.6	Upgrade
Other Financing Activities	-0.73	-0.29	-3.65	-4.25	-0.25	Upgrade
Financing Cash Flow	4.27	8.53	65.69	96.26	0.36	Upgrade
Net Cash Flow	-24.68	18.83	-10.2	-12.13	-28.85	Upgrade
Free Cash Flow	-28.98	-72.35	-64.35	-43.55	-29.21	Upgrade
Free Cash Flow Margin	-7280.15%	-4716.36%	-4130.36%	-3195.08%	-10247.37%	Upgrade
Free Cash Flow Per Share	-18.65	-55.56	-64.60	-72.02	-112.45	Upgrade
Levered Free Cash Flow	-17.53	-39	-33.73	-33.03	-14.45	Upgrade
Unlevered Free Cash Flow	-17.53	-39.14	-33.73	-33.03	-14.45	Upgrade
Change in Working Capital	-2.73	-6.35	-4.89	4.56	13.92	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.